Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Salvador Navarrete has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cirrhosis Regression After Metabolic Bariatric Surgery in Patients With Compensated MASH Cirrhosis

    by Sobia Laique, Awwab F. Hammad, Daniela Allende, Hassan Siddiki, Chase J. Wehrle, Christina C. Lindenmeyer, Saleh Alghsoon, Lindsay Duran, Lisa Durkin, Valentin Mocanu, et al.

    Objective: To evaluate histologic cirrhosis regression after metabolic bariatric surgery (MBS) in patients with compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. Summary Background Data: Cirrhosis in MASH has traditionally been considered irreversible. Although MBS improves steatohepatitis and fibrosis in noncirrhotic MASH, its impact on established cirrhosis remains uncertain. Methods: This retrospective study included adults with biopsy-proven compensated MASH cirrhosis who underwent MBS at Cleveland Clinic from 2004 to 2024 and had paired baseline and follow-up liver biopsies. The primary outcome was regression from NASH Clinical Research Network (NASH CRN) stage 4 to stage 3 or lower. Fibrosis was also assessed using modified Ishak staging and the Beijing classification. Results: Thirty patients were included; 22 (73%) were female, median age was 54.2 years, and median baseline body mass index was 43.7 kg/m². The median (IQR) biopsy interval was 6.2 (2.0–9.2) years, median body weight reduction was 31.8 (21.4–40.4) kg, and median total weight loss was 23.9% (18.0%–30.5%). Cirrhosis regression occurred in 33% of patients using NASH CRN staging and in 40% using modified Ishak staging. Regressive fibrosis features were identified in 60% of patients using the Beijing classification. Significant improvements were also observed in steatosis, lobular inflammation, and hepatocyte ballooning. Conclusions: MBS was associated with histologic cirrhosis regression in a substantial proportion of patients with biopsy-proven compensated MASH cirrhosis. More detailed histologic frameworks identified additional fibrosis improvement and regressive remodeling, suggesting that compensated MASH cirrhosis may be reversible after sustained metabolic intervention.

  • Six-month comparative outcomes of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: an MBSAQIP analysis

    by Valentin Mocanu, Mélissa V. Wills, Xinlei Zhu, Juan S. Barajas-Gamboa, Yung Lee, Andrew Strong, Ricard Corcelles, Matthew Kroh, Jerry Dang, Salvador Navarrete

    Background North American data regarding long-term efficacy and durability of endoscopic sleeve gastroplasty (ESG) are remarkably scarce outside of clinical trial settings hampering our understanding of its optimal role in the obesity care continuum. The aims of this study are to compare safety and efficacy of elective ESG versus laparoscopic sleeve gastrectomy (LSG) at 6 months using accredited MBSAQIP centers. Methods Data were obtained from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database for 2023 and merged with the 6‑month follow‑up data file. The primary objectives of the study were to characterize the long-term six-month changes in weight and metabolic comorbidities of ESG patients in contrast to their LSG counterparts. Logistic regression models were to evaluate for differences in six-month serious complications and emergency department readmissions between ESG and LSG. Results A total of 115,476 patients were included, comprising 114,967 LSG and 509 ESG procedures. Patients undergoing ESG were slightly older (44.5 ± 11.2 vs. 42.4 ± 11.9 years, p = 0.0001) and had lower baseline BMI (40.9 ± 8.6 vs. 45.0 ± 7.8 kg/m2, p < 0.0001) and mean body weight (113.2 ± 28 vs. 124.5 ± 26.3 kg). At 6 months, LSG resulted in greater weight reduction, with larger BMI loss (8.2 ± 10.8 vs. 3.9 ± 12.0 kg/m2, p < 0.0001), and total weight loss (22.6 ± 35.6 vs. 11.1 ± 37.7 kg, p < 0.0001). For patients undergoing LSG, there was a near 50% reduction in medication/insulin-dependent diabetes along with improvements in rates of dyslipidemia, hypertension, and sleep apnea. Importantly, no clinically meaningful comorbidity improvements from baseline to 6 months were seen following ESG. Conclusion When compared to ESG at 6 months, LSG provides an improvement in total body weight loss, has a reduced operative time, and is associated with dramatic metabolic comorbidity improvement including a reduction in resolution of medication and insulin-dependent diabetes. No clinically meaningful comorbidity resolution was seen in patients receiving ESG compared to LSG at 6 months although this cohort was less comorbid at baseline.

  • Open Access

    Anastomotic marginal ulceration after conversion of sleeve gastrectomy to Roux-en-Y gastric bypass

    by Fadlullah Ba'TH, Xiaoxi Feng, Jesse Gutnick, Toms Augustin, Rickesha Wilson, Jerry T. Dang, Andrew T. Strong, Walter Cha, Kalman Bencsath, Chao Tu, et al.


  • Robotic primary Roux-en-Y gastric bypass is independently associated with increased 30-day mortality: a 2023 MBSAQIP analysis of 50,365 patients

    by Valentin Mocanu, Mélissa V. Wills, Salvador Navarrete, Pattharasai Kachornvitaya, Xinlei Zhu, Andrew Strong, Matthew Kroh, Jerry Dang


  • Open Access

    Heart Failure Independently Predicts Higher Morbidity and Mortality Following Bariatric Surgery: Analysis of 180,544 MBSAQIP Cases

    by Juan S. Barajas-Gamboa, Valentin Mocanu, Kayanne Khoury, Mélissa V. Wills, Pattharasai Kachornvitaya, Sol Lee, Thomas H. Shin, Matthew Allemang, Andrew T. Strong, Salvador Navarrete, et al.

    Introduction: Heart failure (HF) and obesity represent intersecting public health epidemics with significant healthcare implications. As obesity-related heart failure becomes increasingly prevalent, understanding the perioperative risks and outcomes of bariatric surgery in this vulnerable population is essential. This study aimed to analyze procedure-specific outcomes and cardiac complications in heart failure patients undergoing primary bariatric surgery using a large multi-institutional database. Methods and Procedures: We conducted a retrospective analysis using the 2023 MBSAQIP database, examining adult patients who underwent primary laparoscopic bariatric procedures (sleeve gastrectomy or Roux-en-Y gastric bypass). Patients were stratified into heart failure and non-heart failure cohorts. The primary outcomes evaluated were 30-day serious complications and mortality. Multivariable logistic regression analyses were performed to identify independent predictors of complications and mortality, adjusting for demographics, comorbidities, and operative factors. Results: Among 180,544 patients, 2,842 (1.6%) had pre-existing heart failure documented preoperatively. HF patients were significantly older (53.3 ± 11.0 vs. 42.8 ± 11.8 years, p < 0.001) with higher BMI (48.6 ± 9.5 vs. 45.0 ± 7.7 kg/m², p < 0.001) and greater comorbidity burden. Procedure distribution was similar between groups (SG: 70.7% vs. 72.1%, RYGB: 29.3% vs. 27.9%, p = 0.091). HF patients experienced significantly higher rates of serious complications (7.2% vs. 2.4%, p < 0.001) and mortality (0.74% vs. 0.06%, p < 0.001). Cardiac events occurred 13 times more frequently in HF patients (1.3% vs. 0.1%, p < 0.001). Hospital length of stay was longer (1.9 ± 2.9 vs. 1.2 ± 1.0 days, p < 0.001), with higher readmission rates (7.8% vs. 2.8%, p < 0.001). On multivariable analysis, pre-existing HF was the strongest independent predictor of serious complications (OR 1.81; 95% CI 1.55–2.13; p < 0.001) and a powerful predictor of 30-day mortality (OR 3.64; 95% CI 2.14–6.20; p < 0.001). Conclusion: Heart failure is a major independent predictor of both serious complications and mortality following bariatric surgery, occurring in nearly 2% of all elective cases. Despite the established long-term benefits of bariatric surgery for HF patients, the substantially elevated perioperative risks require careful patient selection, thorough preoperative cardiac assessment, and specialized perioperative management strategies to optimize outcomes in this high-risk population.


  • Left ventricular assist devices triple the risk of serious complications and longer hospital stay following bariatric surgery: a national analysis of 180,544 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program cases

    by Juan S. Barajas-Gamboa, Valentin Mocanu, Mélissa V. Wills, Gabriela Restrepo-Rodas, Pattharasai Kachornvitaya, Xinlei Zhu, Sol Lee, Thomas H. Shin, Gustavo Romero-Velez, Matthew Allemang, et al.


  • Robotic RYGB is Associated with Increased Risk of Early Postoperative Small Bowel Obstruction: an Analysis of 188,213 MBSAQIP Cases

    by Juan S. Barajas-Gamboa, Valentin Mocanu, Gabriela Restrepo-Rodas, Mélissa V. Wills, Pattharasai Kachornvitaya, Sol Lee, Thomas H. Shin, Xinlei Zhu, Matthew Allemang, Andrew T. Strong, et al.

    Introduction Small bowel obstruction (SBO) represents a serious early complication following Roux-en-Y gastric bypass (RYGB) surgery. With the widespread adoption of robotic platforms in bariatric surgery, understanding the impact of robotic assistance on postoperative complications has become increasingly important. However, the association between robotic assistance and early SBO risk remains unclear in the current literature. This study aimed to evaluate the relationship between robotic assistance and early postoperative small bowel obstruction following primary RYGB procedures. Methods and Procedures We conducted a retrospective cohort study analyzing the 2020–2023 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database from over 900 accredited bariatric surgery centers across the United States and Canada. Patients undergoing primary RYGB were stratified by occurrence of 30-day SBO. The primary outcomes evaluated were early postoperative small bowel obstruction rates, reoperation rates, and readmission rates. Multivariable logistic regression was used to identify independent predictors of SBO, adjusting for patient demographics, comorbidities, and operative factors. Results A total of 188,213 RYGB procedures were included in the study, with 1,704 patients (0.9%) developing early SBO. Robotic assistance was utilized in 29.2% of cases. Baseline characteristics showed that SBO patients were predominantly female (90.1% vs. 83.4%, p < 0.001) with lower BMI (43.6 vs. 45.5 kg/m², p < 0.001) and longer operative times (141.7 vs. 124.7 min, p < 0.001). SBO occurred more frequently with robotic assistance compared to conventional approaches (1.2% vs. 0.8%, p < 0.001), representing an absolute risk difference of 0.4% or approximately 4 additional SBO cases per 1,000 robotic procedures. Multivariable analysis confirmed robotic assistance as an independent risk factor for early SBO (OR 1.30, 95% CI 1.17–1.44, p < 0.001), alongside female sex (OR 1.76) and VTE history (OR 1.55). SBO cases showed significantly higher reoperation rates (54.7% vs. 1.2%) and readmission rates (75.1% vs. 4.1%) compared to patients without SBO. Conclusion Robotic assistance is independently associated with increased early SBO risk following RYGB (OR 1.30, absolute risk 1.2% vs. 0.8%, 4 additional cases per 1,000 procedures). While the absolute risk increase is modest, these findings necessitate balanced patient counseling that incorporates both this increased early SBO risk and potential benefits of robotic approaches. These results support the development of standardized robotic protocols to mitigate SBO occurrence while leveraging the advantages of robotic technology in bariatric surgery centers.


  • Open Access

    Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Risk-Adjusted Safety Profiles after Previous Fundoplication: A 499-Patient MBSAQIP Analysis

    by Pattharasai Kachornvitaya, Valentin Mocanu, Mélissa V. Wills, Juan S. Barajas-Gamboa, Salvador Navarrete, Ricard Corcelles, Andrew Strong, Suthep Udomsawaengsup, Matthew Kroh, Jerry Dang

    Background: Obesity and gastroesophageal reflux disease (GERD) frequently coexist and may necessitate surgical intervention when conservative management fails. While fundoplication is effective for GERD, many patients ultimately require metabolic and bariatric surgery (MBS) for obesity. The safety and prevalence of sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) after prior fundoplication remains poorly characterized. Objectives: To assess the prevalence and 30-day serious complication rates of SG and RYGB following fundoplication, and to identify independent predictors of adverse outcomes. Methods: A retrospective analysis of the 2022–2023 MBSAQIP database identified 499 patients undergoing primary SG or RYGB after fundoplication. Outcomes assessed included leak, bleeding, reoperation, reintervention, cardiac events, pneumonia, kidney injury, thromboembolism, infection, or sepsis. Multivariable logistic regression was used to adjust for baseline differences. Results: Of 499 patients, 126 (25.3%) underwent SG (F-SG) and 373 (74.7%) underwent RYGB (F-RYGB). Concomitant paraesophageal hernia repair was more common in the F-RYGB group (54.2% vs. 26.2%, p < 0.001). Mean BMI was higher in F-SG (42.4 vs. 40.1 kg/m², p < 0.001). Weight gain and GERD were the leading indications for revisional bariatric surgery. F-RYGB was associated with longer operative times, hospital stay, and higher rates of reoperation, readmission, bowel obstruction, and serious complications (9.6% vs. 4.0%, p = 0.045). Rates of anastomotic leak, postoperative bleeding, and composite wound complications were low but numerically higher in F-RYGB, without statistical significance. In multivariate analysis, procedure type was not significantly associated with serious complications (OR 2.03, 95% CI 0.68–6.09, p = 0.207). Conclusions: Both SG and RYGB appear to be safe and effective revisional options, and a history of fundoplication should not be considered a contraindication. Although RYGB was associated with longer operative times and higher early complication rates, multivariable analysis showed no significant difference in serious complications between the two procedures.


  • Open Access

    Conversion for Severe Malnutrition After Single Anastomosis Duodeno-Ileostomy with Sleeve Gastrectomy (SADI-S) to Duodenojejunal Bypass (DJB): a Case Series and Literature Review

    by Sol Lee, Ina Chen, Mélissa V. Wills, Matthew Kroh, Ali Aminian, Salvador Navarrete

    Single Anastomosis Duodeno-ileostomy with Sleeve Gastrectomy (SADI-S) is an emerging bariatric procedure that can sometimes lead to severe malnutrition. This report describes two cases of conversion surgery for post-SADI-S malnutrition and reviews management strategies. Both patients, who had undergone sleeve gastrectomy followed by SADI-S for weight recurrence, developed severe protein-energy malnutrition with hypoalbuminemia (1.6–1.8 g/dL) requiring parenteral nutrition, which normalized following conversion surgery. They underwent laparoscopic conversion to Roux-en-Y duodenojejunal bypass with common channel lengthening (Case 1: 200→550 cm, Case 2: 250→750 cm). Postoperatively, both recovered without needing parenteral support. Our technique provides significant clinical advantages through reduced operative complexity and avoidance of challenging duodenal stump management while achieving excellent nutritional outcomes. While this demonstrates the potential of surgical intervention in managing severe post-SADI-S malnutrition, the current absence of standardized protocols for post-SADI-S conversional surgery underscores the clear necessity for evidence-based treatment algorithms through multicenter research.